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Summary 
 
 An experiment was conducted to evaluate 
the interaction between steroidal implantation 
and feeding ractopamine on nitrogen reten-
tion, blood metabolites, and messenger RNA 
(mRNA) expression.  Six Holstein steers (ini-
tially weighing 509 lb) were implanted or not 
with Revalor-S (120 mg trenbolone acetate 
plus 24 mg estradiol-17β), and all were fed no 
ractopamine for the initial 28 days and then 2 
grams per steer daily of Optaflexx (200 
mg/day ractopamine-HCl) on days 29 through 
56.  Implantation increased nitrogen retention.  
Optaflexx increased nitrogen retention in non-
implanted steers, but did not significantly in-
crease retained nitrogen in implanted steers.  
Implantation increased serum insulin-like 
growth factor (IGF)-I concentration. Op-
taflexx, however, numerically decreased se-
rum IGF-I concentrations.  Implantation nu-
merically increased IGF-I mRNA in the long-
issimus muscle, but expression of IGF-I 
mRNA was significantly decreased when Op-
taflexx was fed.   Both growth promotants in-
creased nitrogen retention in steers, but, de-
spite perceived differences in their mode of 
action, the combination yielded a less than 
additive response for nitrogen retention. 
 
Introduction 
 
 In the feedlot industry, enhancing effi-
ciency of growth of finishing cattle is a major 
objective.  Improvements in growth have been 
achieved by use of steroidal implants.  Ster-
oidal implants such as Revalor-S that contain 
trenbolone acetate and estradiol-17β can im-
prove daily gain and feed efficiency, which 
results, at least in part, from increased blood 
concentrations of IGF-I and local tissue pro-
duction of IGF-I.  Insulin-like growth factor-I 
affects postnatal muscle growth by increasing 
the number of satellite cells (which contain 
DNA), fusion of these satellite cells with ex-
isting muscle fibers, and muscle protein 
accretion. 
 
 Optaflexx is growth promotant that is new 
to the market in the United States.  Optaflexx 
is the trade name for ractopamine-HCl, a β1 
adrenergic agonist.  Addition of Optaflexx to 
the diet can repartition nutrients away from fat 
deposition and to muscle accretion, thus im-
proving daily gain and feed efficiency.  Little 
research has been conducted with steers that 
have been implanted with Revalor-S and fed 
Optaflexx.   
 
 Implants and β agonists may improve 
growth by potentially different mechanisms.  
Previous research has shown that implanting 
steers with Revalor-S increases serum concen-
trations of IGF-I, and this effect is maintained 
for up to 150 days.  Similarly, mRNA expres-
sion of IGF-I in the longissimus and the liver 
of steers implanted with Revalor-S is signifi-
cantly increased by implantation.  As a result 
 
         
 
 1Revalor is a registered trademark of Intervet, Inc. 
 2Optaflexx is a registered trademark of Elanco Animal Heath, Indianapolis, IN. 
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of these increases in IGF-I, daily gain and feed 
efficiency are improved.  Insulin-like growth 
factor-I improves muscle growth by increasing 
protein accretion and by increasing the DNA 
content in the muscle, which is needed to sus-
tain the increased protein accretion.  Optaflexx 
has been shown to improve daily gain and 
feed efficiency in feedlot cattle, but the 
mechanisms involved have not been com-
pletely elucidated.  For example, the impact of 
Optaflexx on IGF-I measures has not been 
documented. 
 
 The aim of our study was to evaluate ef-
fects of feeding Optaflexx to steers implanted 
with Revalor-S and, thus, evaluate some 
mechanisms of action for these growth promo-
tants in an effort to predict if they might yield 
additive or synergistic responses.  For our 
study, growing Holstein steers were used as a 
research model to provide some insight into 
the mechanisms by which these two growth 
promotants function.   
 
Experimental Procedures 
 
 Six Holstein steers (509 lb initial weight) 
were used in a split-plot design.  Steers were 
housed in individual metabolism crates and 
were adapted to a corn-based diet for 1 week 
before the study.  All steers had free access to 
water and received the same diet in equal pro-
portions at 12-hour intervals during the ex-
periment.  The diet contained 62% dry rolled 
corn, 15% alfalfa hay, and 20% expeller soy-
bean meal.  Rumensin (30 mg/kg) and tylan 
(11 mg/kg) were added to the diet.  The diet 
was formulated to supply excess metaboliz-
able protein to the steers.  
 
 The main plot treatments were implanta-
tion with Revalor-S (120 mg trenbolone ace-
tate plus 24 mg estradiol-17β; Intervet, Mills-
boro, DE) or no implant.  Three of the six 
steers were implanted on day 0.  The subplot  
 
treatment was feeding of 0 or 2 grams per 
steer daily of Optaflexx (providing 0 or 200 
mg/day ractopamine-HCl; Elanco Animal 
Health, Greenfield, IN).  None of the steers 
received Optaflexx during the initial 28 days 
of the trial, and then all steers were fed 2 
grams per steer daily of Optaflexx, beginning 
on day 29 and continuing through the end of 
the trial. 
 
 Representative samples of the diet, orts, 
feces, and urine were collected over 4-day pe-
riods for measuring nitrogen balance (a meas-
ure of lean-tissue deposition).  Jugular blood 
samples were collected 2 hours after the morn-
ing feeding on days 0, 14, 28, 42, and 56 for 
analysis of glucose, urea, insulin, and IGF-I.  
Biopsy samples were collected from the long-
issimus muscle of each steer on days 0, 14, 28, 
42, and 56. Semimembranous muscle and 
liver samples were collected from each steer 
after they were euthanized on day 56.  Total 
RNA was isolated from muscle and liver sam-
ples for use in real-time, quantitative poly-
merase chain reaction (PCR) to measure the 
expression of IGF-I mRNA.   
 
Results and Discussion 
 
 Optaflexx significantly increased diet di-
gestibility and significantly decreased nitrogen 
intake, fecal nitrogen excretion, and urinary 
urea nitrogen excretion (Table 1).  Decreases 
in N intake were a result of slightly lower die-
tary N concentrations during the second half 
of the experiment.  An increase in digestibility 
would lead to less fecal nitrogen loss.  Total 
urinary nitrogen excretion was significantly 
decreased by Revalor-S and by feeding Op-
taflexx to control steers; it was not, however, 
affected by feeding Optaflexx to steers im-
planted with Revalor-S.  Increases in diet di-
gestibility and decreases in nitrogen excretion 
led to significant increases in nitrogen reten-
tion in response to Revalor-S as well as in  
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response to Optaflexx in non-implanted steers, 
but not in response to Optaflexx in implanted 
steers (Figure 1). 
 
 Plasma urea and glucose concentrations 
were not significantly affected by treatment 
(Table 2).  Plasma insulin concentrations were 
not significantly affected by Revalor-S or Op-
taflexx, but numerically concentration de-
creased 66% in implanted steers when Op-
taflexx was fed, in contrast to an 8% decrease 
in non-implanted steers in response to Op-
taflexx.  Implantation with Revalor-S signifi-
cantly increased serum IGF-I concentrations.  
In contrast, Optaflexx led to numerical de-
creases in serum IGF-I concentrations in both 
control and implanted steers.  During the final 
28 days, when Optaflexx was fed, implanted 
steers maintained greater serum IGF-I concen-
trations than control steers did.  
 
 Messenger RNA is the product of gene 
expression and is the first of many steps in 
producing a protein.  Measuring mRNA ex-
pression of a gene is not a direct measure of 
the protein produced, but it typically is related 
to production of the protein.  Insulin-like 
growth factor-I mRNA expression in the long-
issimus muscle followed the same pattern as 
serum concentrations of IGF-I (Table 2).  Im-
plantation with Revalor-S led to numerical 
increases in IGF-I mRNA expression, but 
IGF-I mRNA expression in longissimus mus-
cle was significantly decreased by Optaflexx.  
During the final 28 days, when Optaflexx was 
fed, implanted steers maintained greater IGF-I 
mRNA expression than control steers did.  
Implantation with Revalor-S resulted in nu-
merical increases in IGF-I mRNA expression 
in semimembranosus muscle tissue on day 56 
(Table 3).  Revalor-S also led to numerical 
increases in IGF-I mRNA in the liver on day 
56 (Table 3), which agrees with the higher se-
rum IGF-I concentrations that implanted steers 
maintained throughout the study.  Because the 
liver is the primary source of blood IGF-I, the 
relationship between liver mRNA expression 
and serum concentrations of IGF-I was ex-
pected.  
 
 The results gathered from this experiment 
show that Revalor-S or Optaflexx can improve 
growth in lightweight, growing Holstein 
steers, as shown by improvements in nitrogen 
retention.  Administering a combination of the 
two, however, did not enhance nitrogen reten-
tion beyond that observed for the implant 
alone.  The two growth promotants demon-
strated different modes of action; Revalor-S 
increased serum concentrations and mRNA 
expression of IGF-I, whereas Optaflexx led to 
decreases in these parameters.  Although our 
steers were not typical of finishing cattle that 
would receive Optaflexx (they were much 
smaller and more recently implanted), the use 
of these animals allowed an evaluation of the 
mechanisms of action of the two growth  
promotants.  
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Figure 1.  Effects of Revalor-S and Optaflexx on nitrogen retention over time in Holstein 
steers.  Filled symbols represent times when Optaflexx was not fed, whereas the open symbols 
represent times when Optaflexx was fed.  Each value represents an average of nitrogen retained 
over four days.  SEM = 1.4. 
 
 
 
Table 1.  Effects of Revalor-S and Optaflexx on nitrogen balance and diet digestibility in 
growing steers 
 
Days 0 to 28 
No Optaflexx 
Days 29 to 56 
2 g/d Optaflexx 
 
Nitrogen, grams/day No Implant Revalor-S No Implant Revalor-S SEM 
Dietary intakea 143.2 140.4 139.6 135.6 3.9 
Fecala 35.2 35.4 29.1 29.9 2.9 
Urinaryb 77.2z 60.8x 71.2y 60.2x 4.0 
Retainedb 30.4x 44.6z 39.0y 45.9z 1.4 
Dry matter digestibility, %a 76.9 77.7 79.0 80.2 1.9 
aEffect of Optaflexx, P<0.05. 
bEffect of Revalor-S × Optaflexx interaction, P<0.05. 
x,y,zMeans having different superscript letters within a row differ, P<0.05.  
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aEffect of Revalor-S, P<0.05. 
bEffect of Optaflexx, P<0.05. 
Table 2.  Effects of Revalor-S and Optaflexx on blood metabolites and IGF-I mRNA 
expression in Holstein steers 
 
Days 14 and 28 
No Optaflexx  
Days 42 and 56 
2 g/d Optaflexx  
Item No Implant Revalor-S  No Implant Revalor-S SEM 
Plasma glucose, mM 4.81 4.64  4.72 4.36 0.2 
Plasma urea, mM 4.60 4.24 4.30 4.02 0.3 
Serum insulin, ng/mL 0.50 0.40 0.46 0.14 0.1 
Serum IGF-I, ng/mLa 443 593 359 545 93 
Longissimus mRNA      
   IGF-I, arbitrary unitsb 516 838 218 453 181 
Table 3.  Effects of Revalor-S on mRNA expression in semimembranosus muscle and liver 
Tissue No Implant Revalor-S SEM 
 --- IGF-I mRNA, arbitrary units ---  
Semimembranosus muscle 956 3,288 792 
Liver 37,252 78,554 19,536 
